Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000343616

Medchemexpress LLC CHMFL-FLT3-122 | 1839150-56-9 | 98.5% | 471.55 | 1 ML
SDP

Catalog No. 5000343616
Encompass_Preferred

CHMFL-FLT3-122 is a potent, selective, and orally active FLT3 kinase inhibitor with an IC50 of 40 nM. It demonstrates selectivity for FLT3 over BTK and c-KIT kinases. This compound induces apoptosis by arresting the cell cycle in the G0/G1 phase and has shown to significantly inhibit the proliferation of FLT3-ITD positive acute myeloid leukemia (AML) cancer cell lines in in vitro studies. In in vivo studies, it suppressed tumor progression without significantly affecting body weight.

  • Potent and selective FLT3 kinase inhibitor
  • Orally active
  • Induces apoptosis by arresting cell cycle in G0/G1 phase
  • Inhibits proliferation of FLT3-ITD positive AML cell lines
  • Inhibits FLT3 auto-phosphorylation, Stat5, ERK, AKT phosphorylation, and cMYC expression
  • Suppresses tumor progression in in vivo models

Catalog No. 50-003-43616 Supplier Medchemexpress LLC Supplier No. HY11029350MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

CHMFL-FLT3-122 is a potent, selective, and orally active FLT3 kinase inhibitor with an IC50 of 40 nM. It demonstrates selectivity for FLT3 over BTK and c-KIT kinases. This compound induces apoptosis by arresting the cell cycle in the G0/G1 phase and has shown to significantly inhibit the proliferation of FLT3-ITD positive acute myeloid leukemia (AML) cancer cell lines in in vitro studies. In in vivo studies, it suppressed tumor progression without significantly affecting body weight.

  • Potent and selective FLT3 kinase inhibitor
  • Orally active
  • Induces apoptosis by arresting cell cycle in G0/G1 phase
  • Inhibits proliferation of FLT3-ITD positive AML cell lines
  • Inhibits FLT3 auto-phosphorylation, Stat5, ERK, AKT phosphorylation, and cMYC expression
  • Suppresses tumor progression in in vivo models

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.